Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2020 08:00 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference

SEATTLE, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer...
January 22, 2020 08:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2020

SEATTLE, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS) today issued the following letter from Dr. Steven C. Quay, President and CEO, to Atossa shareholders: To Our...
January 06, 2020 08:00 ET | Source: Atossa Therapeutics, Inc.

Atossa Genetics Announces Corporate Name Change to Atossa Therapeutics, Inc.

SEATTLE, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer...
December 19, 2019 08:30 ET | Source: Atossa Genetics Inc.

Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women

SEATTLE, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
December 05, 2019 08:30 ET | Source: Atossa Genetics Inc.

Atossa Genetics to Present at the LD Micro 12th Annual Main Event on December 10, 2019

SEATTLE, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
November 13, 2019 08:00 ET | Source: Atossa Genetics Inc.

Atossa Genetics Announces Third Quarter 2019 Financial Results and Provides Company Update

SEATTLE, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer...
October 23, 2019 08:30 ET | Source: Atossa Genetics Inc.

Atossa Genetics to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference

SEATTLE, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
October 16, 2019 08:30 ET | Source: Atossa Genetics Inc.

Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology

SEATTLE and ENCINO, Calif., Oct. 16, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for...
September 30, 2019 08:30 ET | Source: Atossa Genetics Inc.

Atossa Genetics Announces Preliminary Results from Phase 1 Study of Modified-Release Tablet Oral Endoxifen

SEATTLE, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
September 06, 2019 08:30 ET | Source: Atossa Genetics Inc.

Atossa Genetics to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference

SEATTLE, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...